{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001869105","name":"BridgeBio Oncology Therapeutics, Inc.","summary":"BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biotechnology company developing orally bioavailable small molecule inhibitors targeting RAS and PI3K oncogenes. Its pipeline includes BBO-8520 (dual KRAS G12C ON/OFF inhibitor), BBO-11818 (pan-KRAS ON/OFF inhibitor), and BBO-10203 (RAS:PI3K Breaker). These candidates are being evaluated in Phase 1 trials for NSCLC, KRAS mutant solid tumors, HER2+ breast cancer, HR+/HER2- breast cancer, and KRAS mutant colorectal cancer.","people":[],"products":[{"name":"BBO-8520","type":"platform","description":"Orally bioavailable dual KRAS G12C ON/OFF covalent inhibitor evaluated in Phase 1 ONKORAS-101 trial for locally advanced or metastatic NSCLC with KRAS G12C mutation."},{"name":"BBO-11818","type":"platform","description":"Orally bioavailable pan-KRAS ON/OFF inhibitor targeting G12D, G12V, G12C, and WT KRAS; evaluated in Phase 1 KONQUER-101 trial for KRAS mutant solid tumors."},{"name":"BBO-10203","type":"platform","description":"Oral RAS:PI3K Breaker targeting the RAS-binding domain of PI3K; evaluated in Phase 1 BREAKER-101 trial for HER2+ breast cancer, HR+/HER2- breast cancer, and KRAS mutant CRC."}],"partnerships":[{"partner_name":"Merck (pembrolizumab)","partnership_type":"development","description":"BBO-8520 is being evaluated in combination with pembrolizumab in the ONKORAS-101 Phase 1 trial for KRAS G12C mutant NSCLC.","start_date":null},{"partner_name":"Genentech/Roche (trastuzumab)","partnership_type":"development","description":"BBO-10203 is being evaluated in combination with trastuzumab in the BREAKER-101 Phase 1 trial for HER2+ breast cancer.","start_date":null},{"partner_name":"AstraZeneca/Fulvestrant","partnership_type":"development","description":"BBO-10203 evaluated in combination with fulvestrant in BREAKER-101 for HR+/HER2- breast cancer.","start_date":null},{"partner_name":"Novartis (ribociclib)","partnership_type":"development","description":"BBO-10203 evaluated in combination with ribociclib in BREAKER-101 for HR+/HER2- breast cancer.","start_date":null}],"affiliations":[],"origin":{"leaf":"8bb38fcd680e32befd7ae8621f09e58d6c64225fcf0833d6b035e322a88bfd19","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"cb52973adbc872ab38ab10babf94ff8caa85f9fae2bbf5a507100bf36ea214d9","parent":"825bc0f2067371684180a0df8d4e1943acd8dbf8474bc29e0159b87e5277b1c9","source":"0001193125-26-094112","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":116,"hourly_limit":500,"remaining":384,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}